Literature DB >> 2843489

Definitive radiation therapy in bile duct carcinoma.

J K Hayes1, M D Sapozink, F J Miller.   

Abstract

Between 1980 and 1985, 24 patients with primary adenocarcinoma of the bile duct were treated with various combinations of surgery, biliary intubation, external irradiation, and transcatheter brachytherapy. Seventy-five percent of tumors were in the proximal bile ducts. Ten patients received no or only palliative radiation, Group 1, whereas 14 patients received definitive courses of radiation (4 by external beam irradiation, 2 by transcatheter irradiation, and 8 by both modalities), Group 2. Survival in Group 1 and Group 2 was significantly different (p less than 0.005) with median survivals of 2.0 and 12.8 months, respectively. This result may be in part due to differences in treatment and in part due to selection bias because the series is small, uncontrolled, and retrospective. Median survival of the 8 patients treated with combined modalities was 13.2 months (range 7.4-30.3) with 4 patients alive 8.7 to 16.2 months, 3 without cholangiographic evidence of disease. Complications of therapy were common, including bacterial sepsis (58%), cholangitis (38%), gastrointestinal bleeding (46%), intra or extrahepatic abscesses (33%), and recurrent biliary obstruction (25%). Cholangitis, hemorrhage, abscesses, and ulcers appeared more frequently in definitively treated patients, whereas recurrent biliary obstruction was absent in this group and frequent in Group 1. Differences in complication rates between groups were not statistically significant. Early diagnosis and management usually reversed a downhill clinical course in patients with abscess and hemorrhage. Both surgical and percutaneous techniques of biliary decompression, the usual initial form of therapy in bile duct cancer, are associated with frequent and serious complications. Although many of our complications may have derived from biliary decompression, it is possible that definitive treatment may have increased the frequency of serious complications.

Entities:  

Mesh:

Year:  1988        PMID: 2843489     DOI: 10.1016/0360-3016(88)90319-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  12 in total

1.  Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma.

Authors:  Noriaki Sagawa; Satoshi Kondo; Toshiaki Morikawa; Shunichi Okushiba; Hiroyuki Katoh
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

2.  Outcomes from combined chemoradiotherapy in unresectable and locally advanced resected cholangiocarcinoma.

Authors:  Eugene Leong; Wei Wen Chen; Evan Ng; Guy Van Hazel; Andrew Mitchell; Nigel Spry
Journal:  J Gastrointest Cancer       Date:  2012-03

3.  A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma.

Authors:  T E Bowling; S M Galbraith; A R Hatfield; J Solano; M F Spittle
Journal:  Gut       Date:  1996-12       Impact factor: 23.059

Review 4.  External beam plus intraoperative irradiation for gastrointestinal cancers.

Authors:  L L Gunderson; D M Nagorney; J A Martenson; J H Donohue; G R Garton; H Nelson; J Fieck
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

5.  HDR-192Ir intraluminal brachytherapy in treatment of malignant obstructive jaundice.

Authors:  Yi Chen; Xiao-Lin Wang; Zhi-Ping Yan; Jie-Min Cheng; Jian-Hua Wang; Gao-Quan Gong; Sheng Qian; Jian-Jun Luo; Qing-Xin Liu
Journal:  World J Gastroenterol       Date:  2004-12-01       Impact factor: 5.742

6.  Chemoradiation for unresectable gall bladder cancer: time to review historic nihilism?

Authors:  Reena Engineer; Tabassum Wadasadawala; Shaesta Mehta; Umesh Mahantshetty; Nilendu Purandare; Venkatesh Rangarajan; Shyam Kishore Shrivastava
Journal:  J Gastrointest Cancer       Date:  2011-12

7.  Comparison of external beam radiation and brachytherapy to external beam radiation alone for unresectable extrahepatic cholangiocarcinoma.

Authors:  Dustin Boothe; Zachary Hopkins; Jonathan Frandsen; Shane Lloyd
Journal:  J Gastrointest Oncol       Date:  2016-08

8.  Clinicopathologic factors influencing survival of patients with bile duct carcinoma: multivariate statistical analysis.

Authors:  M R Bhuiya; Y Nimura; J Kamiya; S Kondo; M Nagino; N Hayakawa
Journal:  World J Surg       Date:  1993 Sep-Oct       Impact factor: 3.352

9.  Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival.

Authors:  H A Pitt; A Nakeeb; R A Abrams; J Coleman; S Piantadosi; C J Yeo; K D Lillemore; J L Cameron
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

10.  Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma.

Authors:  C H Su; S H Tsay; C C Wu; Y M Shyr; K L King; C H Lee; W Y Lui; T J Liu; F K P'eng
Journal:  Ann Surg       Date:  1996-04       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.